Blood-Thinner Drug Xarelto Markets Convenience, But Puts Patients In Grave Danger
One of the first major drug torts of 2015 will center on the controversial anticoagulant medication known as Xarelto. Manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals as well as Bayer Corporation, Xarelto is part of a new breed of blood thinning drugs known as New Oral Anti-Coagulants (NOACs). What’s new is that unlike the longstanding go-to drug Coumadin (Warfarin), this new generation of drugs promises the convenience of freedom from dietary restrictions and the need to monitor blood levels.
There is no data to support prescribing the drug without monitoring its activity in the body. And, now patients are paying the price and experiencing uncontrollable bleeding and other life-threatening side effects.
Xarelto was created to treat up to six different medical conditions that affect the way the body heals and prevents bleeding. These official uses include:
- Reducing risk of stroke in patients with atrial fibrillation
- Treating or reducing reoccurrence of Deep Vein Thrombosis
- Treating or reducing reoccurrence of Pulmonary Embolism
- Preventing the formation of blood clots in patients following knee or hip replacement surgery
Serious Xarelto side-effects, which to this point have no known antidote or treatment, include:
• Gastrointestinal bleeding
• Brain bleeding
• Bloody stool
• Coughing or vomiting up blood
• Other uncontrollable internal bleeding
Controversy surrounding Xarelto dates back to May of 2012, when the Food and Drug Administration (FDA) first voted to consider its approval. While the FDA eventually approved the drug for use in November of 2012, Xarelto received a “black box” warning at the time of its release. A “black box” warning is a distinction reserved only for drugs that carry a significant risk of serious, life-threatening side effects.
Xarelto is also in the same family of medications as Pradaxa, which recently settled over 4,000 individual cases against it, including more than 500 death claims, for $650 million.
Following a recent decision in December of 2014, multiple cases against the manufacturers of Xarelto have been consolidated in the Eastern District Court of Louisiana. This action affected approximately 21 current cases against the manufacturer, and may encourage more patients harmed by Xarelto to come forward and seek compensation.
You may be entitled to compensation
If you or a loved one took the blood-thinning medication Xarelto and have experienced uncontrollable bleeding or any other serious side effect, you may be entitled to compensation. Contact the experienced Dangerous Drug attorneys of The Yost Legal Group at 1-800-YOST-LAW (967-8529) right away.
Drug manufacturers have a responsibility to properly warn patients of potentially dangerous or life-threatening side effects that could occur as a result of taking medication. The manufacturers of Xarelto failed to properly inform medical professionals as well as the general public of the risks they were facing by using this drug.
At The Yost Legal Group, our attorneys know how to aggressively litigate complex Defective Drug cases and can help you receive the maximum compensation available.
You have already been victimized once. Don’t let it happen again. Get the justice you deserve for you and your loved ones. Call The Yost Legal Group today and speak to an attorney for a free initial consultation about your case at 1-800-YOST-LAW (1-800-967-8529).
The Yost Legal Group – Experienced Attorneys Dedicated to Protecting Your Rights.